FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours par response	. 0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BELANOFF JOSEPH K</u>					2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]										neck all X D	ship of Repor applicable) irector		X 10% (Owner	
			RAPEUTICS LTH DRIVE	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/30/2006									Officer (give title below) Chief Executive Officer				
(Street) MENLO (City)	NLO PARK CA 94025					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Lir	e) <mark>X</mark> F	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day			Execution Date,				es Acquired (A) or Of (D) (Instr. 3, 4 and			Beneficially Owned Following		Forn (D) c	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)						
										Code	v	Amount	(A) or (D) Price		ice	Tran	Reported Transaction(s) (Instr. 3 and 4)			(111511.4)
Common Stock 03/30				03/30/2	006		S ⁽¹⁾		900	D		\$4.98		,245,095		D				
Common Stock																300,000		I	Custodian for minor son ⁽²⁾	
Common Stock															300,000		I	Custodian for a minor daughter ⁽²⁾		
Common Stock 03/31/2006 s 900 D \$4.9592 2,244,195 D								D												
			Та	ble II -								osed of,				Own	ed			
1. Title of 2. 3. Transaction Date Execution Date, Security or Exercise (Month/Day/Year) if any				4. Transa	ransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		tr. 3	8. Price Derivativ Security (Instr. 5)	∕e derivative	Ownersh Form: Direct (D) or Indirect (I) (Instr.	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Num of Shar	ber								

Explanation of Responses:

- 1. The sale on this Form 4 was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 15, 2004.
- 2. The Reporting Person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

Remarks:

s/s Fred Kurland, CFO of

Corcept Therapeutics

03/31/2006

Incorporated attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.